Melanoma
Estado: No Reclutando AúnA Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma.
Para inscribirte contáctate a:
[email protected]
Principales Criterios de Inclusión:
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1/Lansky Performance Score ≥ 80% for adolescents (≥ 12 to < 18 years of age).
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the American Joint Committee for Cancer (AJCC) staging system.
- Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
- Participants must be ≥ 12 years of age. Participants who are ≥ 12 years of age and < 18 years of age (adolescents) must weigh ≥ 40 kg at the time of signing the informed consent (assent).
- Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the AJCC staging system (8th edition).»
- Laboratorio:Bristol Myers Squibb
- Área Terapéutica:Oncología
- Fase del estudio:III
- Código de Estudio:CA224-127
- Ver ensayo en Clinical Trials
Viña del Mar
- Oncocentro APYS
Santiago
- Oncovida
Santiago
- FALP
Santiago
- Clínica Vespucio
Santiago
- Centro de Estudios Clinicos SAGA
Santiago
- Bradford Hill
Santiago
- Clínica Alemana de Santiago
Santiago
- Clínica San Carlos de Apoquindo Red Salud UC Christus
Temuco
- James Lind Centro de Investigación del Cancer
Encuentra tu
ensayo clínico
Elige tu área de interés, patología o región, y accede a tu ensayo clínico.
Buscar ensayos >